Tagged with S

Merz Russia You worked for ten years at Schering-Plough—one of the largest pharmaceutical companies in the world. In February of last year, you joined Merz Pharma, a much smaller player. Some may view this as a step down. What attracted you to this organization? First of all, the position itself was very…

Biocodex Russia You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history of working in the luxury goods industry, but no pharmaceutical management experience. How do you navigate the challenge of entering…

Lupin Russia Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to drug registration and establishing the mutual recognition of clinical trials. On a socio-economic level, wow would you describe the synergies…

Biopharmaceutical investments of RVC (RVC BioFund) Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have necessitated the creation of Biofund? Biofund was created on January 24th, 2011. There are two stakeholders in the creation of…

Serbia Serbia has had an undoubtedly troubled history since the breakup of Yugoslavia in the early 1990s. A costly war and ensuing UN sanctions have left the country’s economy a few years behind those of its regional counterparts. The subsequent global financial crisis in the late 2000s resulted in another hit…

Philips Russia After a long history in Philips, this is your first tenure as a regional CEO. Having been at this position for less than a year, what are your impressions of the differing challenges for a regional head relative to a business unit manager? There are quite distinct challenges. As someone…

Bayer Healthcare Pharmaceuticals Russia You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed, and what do you find most striking? The biggest difference is the fact that the government is much more involved…

Pierre Fabre Russia You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new affiliate in Russia? What challenges did you face and how smooth did you find the process? We faced two significant…

Baker & McKenzie Russia Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your assessment of this firm’s positioning on the Russian market today? I would say yes, this has differentiated us from competitors.…

Amgen Russia Since 2006, Russia has witnessed quite a dynamic few years, with sweeping legislative reforms like the Law on Circulation of Medicines and development strategies like Pharma 2020. What have been the specific effects of these and other initiatives on the biopharmaceutical sector and the biopharmaceutical market? If you look at…

Sanofi Russia There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes you have witnessed throughout these five years? There have been several major developments in this market. The most important has…

Watson Pharmaceuticals Watson is one the largest generic players in the US but the international presence of the company is still relatively modest. Watson does not have commercial operations in India but you acquired Sekhsaria Chemicals back in 2006, as well as a formulations plant in Goa from Dr Reddy’s. Could you…